Replies to post #921 on Bristol Myers Squibb (BMY)

[DewDiligence]

BMY/BLUE resubmit bb2121 BLA following May 2020 RTF:

https://www.businesswire.com/news/home/20200729005776/en

This submission provides further details on the Chemistry, Manufacturing and Controls (CMC) module to address the outstanding regulatory requests from the FDA in May 2020 following the original BLA submission from March 2020.